Document:

Q3 2014 10-Q Exhibit 10.1

Exhibit 10.1

Confidential Treatment Requested. Confidential portions of this document have been
redacted and have been separately filed with the Commission.

FIRST AMENDMENT TO 

                  DEVELOPMENT AND SUPPLY AGREEMENT

                  BETWEEN HOSPIRA WORLDWIDE, INC. 

                  and

                  NPS Pharmaceuticals, Inc.

This First Amendment to the Development and Supply Agreement ("Amendment") is made and effective as of May14, 2014
("Amendment Effective Date"), by and between Hospira Worldwide, Inc., ("Hospira") and NPS Pharmaceuticals, Inc. ("NPS").

RECITALS

WHEREAS, Hospira and NPS are parties to that certain Development and Supply Agreement dated as of March 25, 2009 (the
"Agreement"); and 

WHEREAS, in accordance with Section 12.8 of the Agreement, the parties desire to amend the Agreement under the terms and conditions set forth
below.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth in this Amendment, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree that the Agreement is amended as follows:  

1.   Incorporation of the Agreement. The Agreement is incorporated herein by this reference as though the same was set forth in its entirety.  Except as
specifically set forth herein, the Agreement shall remain in full force and effect and its provisions shall be binding on the parties hereto.

2.   Definitions; References.  Certain defined terms are added to the Agreement as indicated below.  Otherwise, all capitalized terms which are not defined
herein shall have the same meanings as set forth in the Agreement.  References to numbered sections and exhibits cited herein refer to specific sections of, and exhibits to, the Agreement,
as amended.

	Section 1.10 is hereby amended to read as follows:  

"1.10."Product" or "Products" shall mean the Drug in final dosage form, for adult or pediatric
indications, packaged in standard flip top vials, meeting the Product Specifications.  The terms "Adult Product" and "Pediatric Product" shall
refer to the Products having the respective dosage forms referred to herein."

	Section 1.16 is hereby amended to read as follows:

"1.16"Territory" shall mean those countries or geographic areas of the world where Company intends to register, import, market,
promote, sell and use the Products."

	A new defined term is added as Section 1.18, "United States" as follows:

CONFIDENTIAL

"1.18."United States means the United States of America, including the District of Columbia, the Commonwealth of Puerto Rico, all territories and
possessions of the United States of America, United States military bases, and any other location over which the FDA has jurisdiction to regulate medicinal products intended for human
use."

3.   Section 3.2 is hereby amended as follows:

	The language of Section 3.2 is hereby designated as sub-section (a).  

	The following sub-section (b) is hereby added to Section 3.2:

"(b)Company shall notify Hospira promptly in the event that it desires to qualify Hospira as a manufacturer of the Products for sale in any country of the
Territory [***]. For the avoidance of doubt, "sale" shall include providing the Products pursuant to the approved by the applicable regulatory authority special access program which
may be also known as "compassionate use," "expanded access" or "named patient supply" program. Where practical, Hospira
shall provide Company with all reasonable additional technical, developmental and regulatory support, including, for example, regulatory support for Company's supplemental regulatory
filings, packaging and product development, labeling, and Regulatory Authority inspections. The parties will agree to the reasonable incremental costs of such additional support in accordance with Section 4.1.  In addition, Company shall reimburse Hospira for its costs incurred for any additional
Regulatory Authority pre-approval inspections of the [***] Site at the rate quoted in Section 7.3."

4.    A new Section 3.3 is added as follows, with existing Section 3.3 being re-designated as Section 3.4:

"3.3Project Manager.  Each party will appoint an authorized individual who will have primary responsibility for day-to-day interactions with the other
party for the activities under the Project ("Project Manager").  Each party will use all reasonable efforts to provide the other party with at least thirty (30) days prior written
notice of any change in its Project Manager.  All communications between Hospira and Company regarding the conduct of the activities under the Project will be addressed to its Project
Manager."  

5.   Section 5.5 is hereby amended by deleting the existing section in its entirety and replacing it with the following new language:

"5.5Product Labeling.  Except as otherwise specified in Section 5.7, Company shall be solely responsible for
the labeling and finished-form packaging of the Product.  All such labeling and packaging shall be in accordance with the Product Specifications.  Hospira shall be responsible for ink jetting of
the lot number on the seal of each vial or syringe."

Page 2 of 9

CONFIDENTIAL

6.   Section 5.7 is hereby amended by deleting the section in its entirety and replacing it with the following new language:

"5.7Delivery.  Hospira shall deliver the Product to Company, [***] Site.  Title to and risk of loss over the Products shall pass to Company at the time
the Product is placed at the disposal of Company's designated carrier at the loading dock of the [***] Site.  Hospira will pack the
Products in bulk, unlabeled vials ("Brite Stock") for transport in conditions which will not adversely affect the Products and will ensure that all shipping cartons are
appropriately marked, labeled or identified for transport, as may be specified in further detail in the Quality Agreement; provided, however, that Hospira shall not deliver any Product
until Hospira has released such Product pursuant to the Product Specifications and/or the Quality Agreement and Company has performed its own quality review and release testing and has
given Hospira its authorization to ship. Company will be responsible for procuring carriage and insurance in an amount [***], for all shipments.  All freight, handling, insurance, duties, taxes
and shipping expense will be borne by [***].  For any shipments ex United States, Company shall be the exporter of record.

 7.   Section 5.8(a) is hereby amended by deleting the sub-section in its entirety and replacing it with the following new sub-section (a):

"(a) Price.  Hospira shall invoice Company for Product it delivers to Company at the price(s) as set forth on Exhibit
5.8.  Each invoice shall reference the price of the Product in effect on the date of Hospira's invoice.  Effective upon [***]
during the Initial Term (and any renewal term thereafter), Hospira shall have the right to increase the price of the Products [***]. Price increases shall be effective for
deliveries [***].  Such increases shall not exceed [***]  Hospira shall use all reasonable efforts to
provide written notice to Company of any anticipated price increase no later than [***]."  

 8.   Article 6 is hereby amended by deleting Sections 6.5 through Section 6.10 in their entirety and replacing them with the following:

"6.5Rolling Forecast.  During [***], Company shall provide to Hospira a good faith, estimated rolling forecast of the quantity of Products that
Company expects to order [***] (each, a "Rolling Forecast").  The first [***] of each Rolling Forecast shall be considered a binding commitment upon Company to
purchase quantities described therein and a binding commitment upon Hospira to produce and deliver such quantities on the delivery dates described therein ("Firm Order
Period").  The last [***] of each Rolling Forecast shall be non-binding upon the parties.  The Project Managers, or their designees, shall review each Rolling Forecast to ensure that
each Rolling Forecast delivered by Company is consistent with the requirements of this Agreement and, if necessary, to use good faith efforts to adjust such Rolling Forecasts in order to meet
Company's ongoing requirements for the Product and to take into account Hospira's manufacturing schedule at the [***] Site.

Page 3 of 9

CONFIDENTIAL

"6.6Purchase Orders.  Company shall submit to Hospira firm purchase orders for the
purchase of Product (each, a "Purchase Order") for the quantities of Product Company intends to purchase and the required delivery date(s); provided, however,
that no delivery date in any Purchase Order shall be less than [***] prior to the requested delivery date.  Hospira shall use all commercially reasonable efforts to
meet the delivery dates set forth in each Purchase Orders.  All Purchase Orders shall reference this Agreement and shall be governed exclusively by the
terms contained herein.  Company shall set forth in each Purchase Order (i) the quantity of Products ordered (ii) the amount of API estimated to be required to fill the Purchase Order (based on yield information provided by Hospira), (iii) the specified delivery date(s) and delivery instructions, and (iv) the price to be paid for the Product.  

"6.7Purchase Order Acceptance.  Hospira will confirm each Purchase order issued in accordance with Section
6.6 within [***] after receipt and shall confirm to Company its acceptance of the Purchase Order, delivery date(s), the quantity of Products ordered and the purchase price to be paid by
Company.  

"6.8Excess Quantities.  Hospira shall accept all Purchase Orders specifying quantities of
Product up to [***] in excess of the quantities listed in the corresponding Firm Order Period.  Hospira shall not be obligated to supply quantities of Product over and above such [***] excess
amount ("Non-Binding Excess") but shall use commercially reasonable efforts to manufacture and deliver to Company all or part of the Non-Binding Excess within [***] of
issuance of the relevant Purchase Order.  In no event, however, shall Hospira be required to supply any Product in excess of its applicable annual Product Supply Commitment.

"6.9Format of Forecasts and Purchase Orders.  Company shall submit each Rolling Forecast and all Purchase
Orders electronically in spreadsheet form and will specify the quantities of Products in units and the Hospira product number (list number/inventory number).

"6.10Minimum Purchase Requirement.  [Intentionally Deleted]. 

"6.11Purchase Order Changes; Cancellations.

 (a)   Changes.  If Company requests that changes be made to any of its Purchase Orders within the Firm Order period, Hospira shall attempt to
accommodate such changes within reasonable manufacturing capabilities and efficiencies. If Hospira can accommodate such changes, Hospira shall advise Company of any costs
associated therewith.  If Company indicates in writing to Hospira that it should proceed to make the changes, Company shall be deemed to have accepted the obligation to pay Hospira for
such costs.  If Hospira cannot accommodate such change, Company shall nonetheless be bound to its original Purchase Orders.  

Page 4 of 9

CONFIDENTIAL

 (b)   Cancellations.  If Company cancels any Purchase Order within the Firm Order Period, Hospira shall be relieved of its manufacturing obligations relating
to such order but Company will not be relieved of its payment obligation unless Hospira agrees to waive such obligation in writing.  Furthermore, if Company does not supply sufficient API to
allow Hospira to fulfill any Purchase Order or acts in any other manner to effectively interfere with Hospira's ability to perform, which shall be deemed to be a breach of this Agreement,
Company shall remain liable for the full amount of the Purchase Order, regardless of whether Hospira manufactures the Product or whether Company takes delivery of the Product."

 9.   Section 8.6 is hereby amended by deleting the existing section in its entirety and replacing it with the following:

"8.6No Consequential Damages. EXCEPT WITH RESPECT TO EACH PARTY'S INDEMNIFICATION OBLIGATIONS HEREUNDER OR BREACHES OF SECTION 11 (CONFIDENTIAL INFORMATION), NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR INDIRECT, INCIDENTAL,
SPECIAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES OR LOST PROFITS RESULTING FROM ANY BREACH OF THIS AGREEMENT, EVEN IF THE PARTY HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES."

 10.   Exhibit 1.9 is hereby amended by deleting the current exhibit in its entirety and replacing it with a new Exhibit 5.8 in the form attached hereto as
Annex 1.

 11.   Exhibit 2.1 is hereby amended by adding a supplemental Exhibit 2.1(a) (Statement of Work
No. 2) for the development of the Pediatric Product.  Exhibit 2.1(a) shall be substantially in the form attached hereto as Annex 2.

 12.   Exhibit 5.8 is hereby amended by deleting the current exhibit in its entirety and replacing it with a new Exhibit 5.8 in the form attached hereto as
Annex 3.

 13.   This Amendment may be executed in three or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one instrument.  The parties may sign and deliver this Amendment by facsimile or sent by electronic mail in portable document format (PDF) and a reproduction of this
Amendment made by facsimile or PDF will have the same effect as a signed and delivered original version.

SIGNATURE PAGE FOLLOWS

Page 5 of 9

CONFIDENTIAL

In Witness Whereof, the parties intending to be bound by the terms and conditions hereof have caused this Amendment to be signed by their duly authorized
representatives as of the date first above written.

	
HOSPIRA WORLDWIDE, INC.
	
NPS PHARMACEUTICALS, INC.

	

By: /s/ Kevin Orfan
	

By: /s/ Joseph Rogus

	

Name:Kevin Orfan
	

Name:Joseph Rogus

	

Title:Vice President, Commercial Alliances

One 2 One Contract Manufacturing Services
	

Title:Sr. VP, Technical Operations & Supply Chain Mgmt

	 	 

   

   

Page 6 of 9

CONFIDENTIAL

ANNEX 1

Exhibit 1.9

Product Specifications

[***]

   

   

   

Page 7 of 9

CONFIDENTIAL

ANNEX 2

Exhibit 2.1(a)

Statement of Work No. 2

[***]

   

   

   

Page 8 of 9

CONFIDENTIAL

ANNEX 3

Exhibit 5.8

Product Pricing

[***]

   

   

   

Page 9 of 9exhibit10_8.htm

EXECUTIVE EMPLOYMENT AGREEMENT

 

THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of August 6, 2014, by and between Kite Realty Group Trust, a Maryland real estate investment trust (the “Company”), and Scott Murray (the “Executive”) and shall be effective as of August 18, 2014.

 

1. Positions, Duties and Term.  The Company hereby agrees to employ the Executive as its Executive Vice President, General Counsel and Corporate Secretary, and the Executive hereby accepts such employment, on the terms and conditions set forth below.

 

1.1 Term.  The Executive’s employment hereunder shall be for a term commencing as of August 18, 2014 and ending as of the earlier of (i) June 30, 2017 or such later date to which the term of this Agreement may be extended pursuant to Section 1.1(a) or (ii) the Termination Date determined in accordance with Section 12.9.

 

(a) Extension of Term.  Unless the Executive’s employment with the Company terminates earlier in accordance with Subsections (c) or (d), or the parties pursuant to Subsection (b) elect not to extend the term, the term of this Agreement automatically shall be extended as of July 1, 2017, and each July 1st thereafter, such that on each such date the term of employment under this Agreement shall be for a one-year period.

 

(b) Election Not to Extend Term.  The Executive or the Board of Trustees of the Company (the “Board”), by written notice delivered to the other, may at any time elect to terminate the automatic extension provision of Subsection (a).  Any such election may be made at any time until the ninety (90) days prior to the date as of which the term would otherwise be extended for an additional one year.  The parties agree that the expiration of this Agreement resulting from the Executive’s notice to the Company in accordance with this Subsection (b) shall not be considered a termination by the Executive for Good Reason or by the Company without Cause under this Agreement; however, the expiration of this Agreement resulting from the Company’s notice to the Executive in accordance with this Subsection (b) shall be treated as a termination by the Company without Cause under this Agreement.

 

(c) Early Termination.  The Company may terminate the Executive’s employment with or without Cause or on account of Disability, with written notice delivered to the Executive from the Board; provided, that, the Company shall have no right to terminate the Executive’s employment on account of Disability if, in the opinion of a qualified physician reasonably acceptable to the Company, it is reasonably certain that the Executive will be able to resume the Executive’s duties on a regular full-time basis within ninety (90) days of the date the Executive receives notice of such termination on account of Disability.  Any termination in accordance with this Section 1.1(c) shall not be, nor shall it be deemed to be, a breach of this Agreement.

 

 

  

1

  

 

(d) Early Resignation.  The Executive may resign from the Company for any reason, including Good Reason.  The Executive shall effect a Good Reason termination by providing at least thirty (30) days’ written notice to the Board of the applicable Good Reason criteria ; provided that the Executive provided written notice of the existence of the condition that is the basis for such Good Reason within ninety (90) days of the first occurrence of such condition; and further provided that if the basis for such Good Reason is correctible and the Company corrects the basis for such Good Reason within thirty (30) days after receipt of such notice of the occurrence of the condition, the Good Reason defect shall be cured, and Executive shall not then have the right to terminate his employment for Good Reason with respect to the occurrence addressed in the written notice.  Notwithstanding the prior sentence, in no event may the Executive effect a Good Reason termination for a condition that is the basis for such Good Reason more than one year after the first occurrence of such condition.

 

(e) Termination and Offices Held.  At the time that the Executive ceases to be an employee of the Company, the Executive agrees that he shall resign from any offices he holds with the Company and any affiliate, including any boards of directors or boards of trustees.

 

1.2 Duties.  The Executive shall faithfully perform for the Company the duties incident to the office of Executive Vice President, General Counsel and Corporate Secretary and shall perform such other duties of an executive, managerial or administrative nature as shall be specified and designated from time to time by the Board, the Executive’s “Reporting Officer” as designated in Schedule 1 and the Company’s Chief Executive Officer (including the performance of services for, and serving on the board of directors of, any affiliate of the Company without any additional compensation).  The Executive shall report to the “Reporting Officer” designated in Schedule 1 subject to the power of the Board or the Chief Executive Officer to change the designated “Reporting Officer.” The Executive shall devote substantially all of the Executive’s business time and effort to the performance of the Executive’s duties hereunder, provided that in no event shall this sentence prohibit the Executive from performing personal and charitable activities and any other activities approved by the Board, so long as such activities do not materially interfere with the Executive’s duties for the Company.  The Board may delegate its authority to take any action under this Agreement to the Compensation Committee of the Board (the “Committee”).

 

2. Compensation.

 

2.1 Salary.  During the term of his employment under this Agreement, the Company shall pay the Executive at an annual rate of $320,000 (the “Base Salary”).  The Base Salary shall be reviewed no less frequently than annually and may be increased at the discretion of the Board or the Committee, as applicable.  Except as otherwise agreed in writing by the Executive, the Base Salary shall not be reduced from the amount previously in effect.  Upon any such increase, the increased amount shall thereafter be deemed to be the Base Salary for purposes of this Agreement.  The Base Salary shall be payable in such installments as shall be consistent with the Company’s payroll procedures for senior executives generally.  Notwithstanding the employment of the Executive by the Company, the Company shall be entitled to pay the Executive from the payroll of any subsidiary of the Company.

 

 

  

2

  

 

2.2 Annual Cash Incentive.  The Executive shall be eligible to receive an annual cash bonus for the Company’s fiscal years ending December 31, 2015 and each December 31 thereafter based on performance objectives established by the Committee each such fiscal year (the “Annual Cash Incentive”).  The Executive’s target Annual Cash Incentive amount for such fiscal years will be the percentage of Base Salary designated as the target by the Committee, which amount shall be at least sixty percent (60%) of the Base Salary then in effect for each applicable year (the “Full-Year Target”).  Notwithstanding the preceding, the Executive’s Annual Cash Incentive, if any, may be below (including zero), at, or above, the target based upon the achievement of the performance objectives, and payment of any such Annual Cash Incentive shall be in accordance with the terms of such program.  Except as otherwise provided in this Agreement, no Annual Cash Incentive will be payable following the Executive’s Termination Date.

 

2.3 Equity Awards.  The Executive shall be entitled to participate in the Kite Realty Group Trust 2013 Equity Incentive Plan, as amended from time to time, and any successor plan thereto, and to receive awards of equity (the “Equity Awards”) pursuant thereto.  Except as provided in Section 4 and Section 5, all other terms of the equity awards shall be governed by the plans and programs and the agreements and other documents pursuant to which such awards were granted.

 

(a) Restricted Share Award.  Subject to approval by the Committee and the terms of the applicable award agreement, promptly following the Executive’s commencement of employment with the Company, the Executive shall receive an Equity Award grant of restricted common shares of the Company in a number substantially equivalent to a value of $300,000 (disregarding any fractional share), as determined by the closing price of a common share of the Company on the New York Stock Exchange on the date that the Executive commences employment with the Company.  The award agreement for this grant of restricted common shares shall provide that twenty percent (20%) of the granted restricted shares will vest on the first anniversary of the date of this grant and on each of the subsequent four (4) anniversary dates, subject to the Executive’s continued employment with the Company on such dates.

 

2.4 Benefits.  During the term of his employment under this Agreement, the Executive shall be permitted to participate in any group life, hospitalization or disability insurance plans, health programs, pension and profit sharing plans and similar benefits that may be available to other senior executives of the Company generally, on the same terms as may be applicable to such other executives, in each case to the extent that the Executive is eligible under the terms of such plans or programs.  During the term of his employment under this Agreement, the Company shall maintain customary liability insurance for trustees and officers and list the Executive as a covered officer.

 

2.5 Vacation.  During the term of his employment under this Agreement, the Executive shall be entitled to vacation in accordance with the Company’s policy.

 

  

3

  

 

2.6 Expenses.  The Company shall pay or reimburse the Executive for all ordinary and reasonable out-of pocket expenses actually incurred (and, in the case of reimbursement, paid) by the Executive during the term of the Executive’s employment under this Agreement, provided that the Executive submits such expenses in accordance with the policies applicable to senior executives of the Company generally.

 

3. Termination for Cause, Executive’s Election Not to Extend Term, or Resignation by the Executive Other than for Good Reason.  In the event of the Executive’s resignation other than for Good Reason, his termination of employment due to his election not to extend the term in accordance with Section 1.1(b), or his termination by the Company for Cause, all obligations of the Company under Sections 1 and 2 will immediately cease as of the Executive’s Termination Date.  In connection with this resignation or termination, within ten (10) days of the Executive’s Termination Date, the Company will pay the Executive the amount of the Executive’s Compensation Accrued at Termination, and the Executive’s rights, if any, under any Company benefit plan or program shall be governed by such plan or program.

 

4. Termination On Account of Death or Disability.  In the event of the Executive’s termination of employment with the Company on account of death or Disability, all obligations of the Company under Sections 1 and 2 will immediately cease as of the Executive’s Termination Date.  In connection with this termination, (a) within ten (10) days of the Executive’s Termination Date, the Company will pay the Executive (or, in the case of the Executive’s death, the Executive’s beneficiary or, if none has been designated in accordance with Section 10.3, the Executive’s estate), (i) the amount of the Executive’s Compensation Accrued at Termination and (ii) a single sum cash payment equal to the Partial Year Bonus; (b) all Equity Awards held by the Executive, other than any Performance-Based Award (defined in Section 5.3(b)) that is designated an “out-performance” award and that references and proclaims to supersede this Agreement and as to which the provisions of such Equity Award shall control, shall become fully vested and exercisable; (c) the benefits described in Section 5.2; and (d) the Executive’s rights, if any, under any Company benefit plan or program shall be governed by such plan or program.  A Performance-Based Award becoming vested under this Section 4 (rather than pursuant to the Equity Award agreement) shall vest at the target level.

 

5. Termination Without Cause or for Good Reason.  If during the term of his employment under this Agreement, the Executive is terminated by the Company without Cause (which includes the Company’s election not to extend the term of this Agreement in accordance with Section 1.1(b)) or resigns from the Company for Good Reason, all obligations of the Company under Sections 1 and 2 will immediately cease as of the Executive’s Termination Date.  In connection with this resignation or termination, within ten (10) days of the Executive’s Termination Date, the Company will pay the Executive the amount of the Executive’s Compensation Accrued at Termination, and the Executive’s rights, if any, under any Company benefit plan or program shall be governed by such plan or program.  In addition, in connection with a resignation or termination described in this Section 5, subject to the requirements of Section 5.4, the Executive shall be entitled to the benefits described in Section 5.1, Section 5.2, and to the extent applicable, Section 5.3.

 

  

4

  

 

5.1 Severance and Bonus.  With respect to a termination of employment under this Section 5 only, the benefits under this Section 5.1 shall consist of the following:

 

(a) A single sum severance cash payment equal to two (2) times the sum of: (i) the Executive’s Base Salary in effect on the Termination Date and (ii) the average Annual Cash Incentive actually paid to the Executive with respect to the prior three (3) fiscal years, which shall be paid to the Executive within sixty (60) days of the Executive’s Termination Date; and

 

(b) A single sum cash payment equal to the Partial Year Bonus; provided, that, no amount may be paid under this Section 5.1(b) unless the Company performance criteria for payment of an Annual Cash Incentive are achieved at the level required for a payout at the Full-Year Target level or above as of the close of the fiscal year in which the Termination Date occurs; and provided, further, that if the Executive’s resignation or termination under this Section 5 follows a Change in Control and occurs during the performance year that includes the Change in Control, the Partial Year Bonus shall be payable without regard to achievement of the performance criteria.

 

5.2 Medical, Prescription, and Dental Benefits.  With respect to a termination of employment under Section 4 and this Section 5 only, the benefits under this Section 5.2 shall consist of continued medical, prescription, and dental benefits to the Executive and/or the Executive’s family at least equal to those which would have been provided to them in accordance with the welfare benefit plans, practices, policies, and programs provided by the Company to the extent applicable generally to other peer employees of the Company and its affiliated companies, as if the Executive’s employment had not been terminated, for eighteen (18) months after the Executive’s Termination Date; provided, however, that if the Executive becomes reemployed with another employer and is eligible to receive medical, prescription, and dental benefits under another employer-provided plan, the medical, prescription, and dental benefits described herein shall be secondary to those provided under such other plan during such applicable period of eligibility.

 

5.3 Accelerated Vesting of Equity Awards.  With respect to a termination of employment under this Section 5 and as otherwise provided in this Employment Agreement, the benefits under this Section 5.3 shall consist of the following:

 

(a) All equity or equity-based awards held by the Executive at termination of employment, including but not limited to, stock options, restricted stock, and restricted stock units, whether or not granted as performance-based awards, and which at the time of termination of employment are subject only to time-vesting based on service (the “Time Vested Awards”), shall become fully vested and non-forfeitable to the extent not already so vested;

 

  

5

  

 

(b) Subject to Section 5.3(c) and the clarification described in the next sentence, with respect to all equity and equity-based awards held by the Executive at termination of employment which are subject to cancellation in the event the stated performance objectives are not satisfied, including but not limited to, stock options, restricted stock, and restricted stock units, and for which at the time of the Executive’s termination of employment, the performance objectives have not been satisfied (the “Performance-Based Awards”), the Performance-Based Awards shall become vested and non-forfeitable on a Pro-Rata Basis, but only if at the end of the performance period, the performance objectives are achieved; provided, however, that if the Executive’s resignation or termination under this Section 5 follows a Change in Control, the Performance-Based Awards outstanding as of such Change in Control and remaining outstanding as of the Executive’s resignation or termination under this Section 5 shall become fully vested and non-forfeitable.  With respect to the provision for vesting and non-forfeiture of an award on a Pro-Rata Basis as described herein, only the performance periods under the award that have already commenced as of the Termination Date shall be taken into account to determine whether the performance objectives ultimately are achieved, and any performance period that has not commenced as of the Termination Date shall be disregarded for purposes of determining whether the award becomes vested and non-forfeitable on a Pro-Rata Basis; and

 

(c) The amount of Performance-Based Awards eligible to become vested under Section 5.3(b) shall be determined by the level of achievement of the performance objectives; provided, however, that if the Performance-Based Award is becoming fully vested and non-forfeitable under Section 5.3(b) on account of a Change in Control, the earnings level shall not be conditioned on awaiting the end of the performance period and achievement of the performance objectives, and instead the performance objectives upon which the earning of the Performance-Based Award is conditioned shall be deemed to have been met at the greater of (i) target level at the Termination Date, or (ii) actual performance at the Termination Date.

 

To the extent that any Performance-Based Award references and proclaims to supersede this Agreement, the provisions of such Equity Awards shall control and supersede this Section 5.3.

 

5.4 Waiver and Release Agreement.  The Executive agrees to execute at the time of the Executive’s termination of employment a Waiver and Release Agreement in a form provided to the Executive by the Company(the “Waiver and Release Agreement”), consistent with the form attached hereto as Exhibit C, the terms and conditions of which are specifically incorporated herein by reference.  The execution and delivery of the Waiver and Release Agreement shall be made within forty-five (45) days of delivery to the Executive of the Waiver and Release Agreement, and the Company shall (a) pay the benefits under Section 5.1(a) and, the event that the Executive’s resignation or termination under this Section 5 results in payment of a Change in Control year Partial Year Bonus, under Section 5.1(b) within ten (10) days after the Waiver and Release Agreement is no longer revocable by the Executive and (b) in the event that the Executive’s resignation or termination under this Section 5 results in payment of a Change in Control year Partial Year Bonus, pay the benefits under Section 5.1(b) within ten (10) days after the Waiver and Release Agreement is no longer revocable by the Executive or, if later, at the same time as payment is made to all other participants under the Annual Cash Incentive program following the close of the fiscal year in which the Termination Date occurs.  If the Waiver and Release Agreement is not executed within the forty-five (45)-day period post-delivery, the Executive will forfeit all benefits provided pursuant to Section 5.1, Section 5.2, and Section 5.3.   If the Waiver and Release Agreement is not received by the Executive within five (5) days of the Executive’s Termination Date it shall not be required and this Section 5.4 shall be null and void.

 

  

6

  

 

6. Nature of Payments.  For the avoidance of doubt, the Executive acknowledges and agrees that the payments set forth in Section 3, Section 4, and Section 5 constitute liquidated damages for termination of his employment during the term of this Agreement (including any extensions thereof).

 

7. Golden Parachute Excise Tax Provisions.  In the event it is determined that any payment or benefit (within the meaning of Section 280G(B)(2) of the Internal Revenue Code of 1986, as amended (the “Code”)), to the Executive or for his or her benefit paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise in connection with, or arising out of, his or her employment (“Payments”), would be subject to the excise tax imposed by Section 4999 of the Code or any interest or penalties are incurred by the Executive with respect to such excise tax (such excise tax, together with any such interest and penalties, are hereinafter collectively referred to as the “Excise Tax”), then the total Payments shall be reduced to the extent the payment of such amounts would cause the Executive’s total termination benefits to constitute an “excess parachute payment” under Section 280G of the Code and by reason of such excess parachute payment the Executive would be subject to an excise tax under Section 4999(a) of the Code, but only if the Executive (or the Executive’s tax advisor) determines that the after-tax value of the termination benefits calculated with the foregoing restriction exceed those calculated without the foregoing restriction.  In that event, the Executive shall designate those rights, payments, or benefits under this Agreement, any other agreements, and any benefit arrangements that should be reduced or eliminated so as to avoid having the payment or benefit to the Executive under this Agreement be deemed to be an excess parachute payment; provided, however, that in order to comply with Section 409A of the Code, the reduction or elimination will be performed in the order in which each dollar of value subject to a right, payment, or benefit reduces the parachute payment to the greatest extent.  Except as otherwise expressly provided herein, all determinations under this Section 7 shall be made at the expense of the Company by a nationally recognized public accounting or consulting firm selected by the Company and subject to the approval of the Executive, which approval shall not be unreasonably withheld.  Such determination shall be binding upon the Executive and the Company.

 

7.1 Company Withholding.  Notwithstanding anything contained in this Agreement to the contrary, in the event that, according to the determinations in the paragraph above, an Excise Tax will be imposed on any Payment or Payments, the Company shall pay to the applicable government taxing authorities as Excise Tax withholding, the amount of the Excise Tax that the Company has actually withheld from the Payment or Payments.

 

8. Confidentiality; Non-Competition and Non-Disclosure; Executive Cooperation; Non-Disparagement.

 

8.1 Confidential Information.  The Executive acknowledges that, during the course of his employment with the Company, the Executive will be given or will become acquainted with Confidential Information (as hereinafter defined) of the Company.  As used in this Section 8.1, “Confidential Information” of the Company means all confidential information, knowledge, or data relating to the Company or any of its affiliates, or to the Company’s or any such affiliate’s respective businesses and investments (including confidential information of others that has come into the possession of the Company or any such affiliate), learned by the Executive heretofore or hereafter directly or indirectly from the Company or any of its affiliates and which is not generally available lawfully and without breach of confidential or other fiduciary obligation to the general public without restriction, except with the Company’s express written consent or as may otherwise be required by law or any legal process.

 

  

7

  

 

The Executive acknowledges that the Confidential Information of the Company, as such may exist from time to time, is a valuable, confidential, special, and unique asset of the Company and its affiliates, expensive to produce and maintain, and essential for the profitable operation of their respective businesses.  The Executive agrees that, during the course of his employment with the Company, or at any time thereafter, he shall not, directly or indirectly, communicate, disclose, or divulge to any Person (as such term is hereinafter defined), or use for his benefit or the benefit of any Person, in any manner, any Confidential Information of the Company or its affiliates, acquired during his employment with the Company or any other confidential information concerning the conduct and details of the businesses of the Company and its affiliates, except as required in the course of his employment with the Company or as otherwise may be required by law.  For the purposes of this Agreement, “Person” shall mean any individual, partnership, corporation, trust, unincorporated association, joint venture, limited liability company, or other entity or any government, governmental agency, or political subdivision.

 

All documents relating to the businesses of the Company and its affiliates including, without limitation, Confidential Information of the Company, whether prepared by the Executive or otherwise coming into the Executive’s possession, are the exclusive property of the Company and such respective affiliates and must not be removed from the premises of the Company, except as required in the course of the Executive’s employment with the Company.  The Executive shall return all such documents (including any copies thereof) to the Company when the Executive ceases to be employed by the Company or upon the earlier request of the Company or the Board.

 

This confidentiality provision shall not restrict the Executive’s right to practice law after the termination of the Executive’s employment for any reason in violation of Rule 5.6 of Indiana’s Rules of Professional Conduct (“RPCs”), and this confidentiality provision shall be interpreted to be consistent with the applicable RPCs.  This confidentiality provision shall not expand the scope of the Executive’s duties to maintain privileged or confidential information in his capacity as an attorney-at-law under Rule 1.6 of the RPCs, Rule 1.9 of the RPCs, or other applicable RPCs to the extent that any such expansion would be inconsistent or in conflict with Rule 5.6 of the RPCs.

 

  

8

  

 

8.2 Noncompetition.  During the term of this Agreement (including any extensions thereof) and, subject to the exceptions set forth in this Section 8.2, for a period of twelve (12) months following the termination of the Executive’s employment under this Agreement for any reason (the “Restricted Period”), the Executive shall not, except with the Company’s express prior written consent, (a) directly or indirectly, engage in any non-legal business employment for any business involving real property development, construction, acquisition, ownership, or operation, whether such business is conducted by the Executive individually or as a principal, partner, member, stockholder, director, trustee, officer, employee, or independent contractor of any Person or (b) own any interests in real property which are competitive, directly or indirectly, with any business carried on by the Company; provided, however, that this Section 8.2 shall not be deemed to prohibit any of the following: (i) any of the real estate (and real estate-related) activities listed on Exhibit A hereto, the Executive’s ownership, marketing, sale, transfer, or exchange of any of the Executive’s interests in any of the properties or entities listed on Exhibit A hereto, or any other permitted activities listed on Exhibit A hereto; and (ii) the direct or indirect ownership by the Executive of up to five percent (5%) of the outstanding equity interests of any public company.  Notwithstanding the foregoing, during the twelve (12)-month “tail” period included in the Restricted Period, the restrictions set forth in this Section 8.2 shall apply only to non-legal business employment (i) with respect to any Person that has been designated as being part of the Company’s peer group, as determined by the Committee and set forth in the most recent proxy statement filed by the Company, or (ii) with respect to any other Person that owns neighborhood  or community shopping centers and with respect to (i) and (ii) only within the following “Restricted Areas”: (A) the states of Indiana, Florida, and Texas; (B) the area within a ten (10)-mile radius of any property owned or leased by the Company, as of the Executive’s Termination Date; (C) each county in each state in which the Company owns or leases property as of the Executive’s Termination Date; and (D) in any state in which the Company owns or leases at least five (5) properties as of the Executive’s Termination Date, the area within a fifty (50)-mile radius of any property owned or leased by the Company, as of the Executive’s Termination Date.  Notwithstanding anything to the contrary in this Section 8.2, during the period beginning twelve (12) months following a Change in Control consummated on or after the date of signing this Agreement (the “Effective Time”), and ending twelve (12) months after such Effective Time, the Executive may resign without Good Reason, and this Section 8.2 shall not apply.  For the avoidance of doubt, this Section 8.2 shall apply in all events if the Executive’s resignation is on account of Good Reason or if the Executive is terminated by the Company for any reason whether  before or following a Change in Control.

 

Notwithstanding anything to the contrary in this Section 8.2, in compliance with Rule 5.6 of the RPCs, this noncompetition provision does not apply to the Executive’s ability to practice law on behalf of any future client, including as in-house or general counsel, so long as such practice of law is otherwise consistent with the RPCs governing duties to former clients.  Rather, this noncompetition provision only applies to limit the Executive’s ability to work in a non-legal business capacity subject to the requirements and exceptions as stated in this Section 8.2.

 

8.3 Non-Solicitation.  During the term of this Agreement (including any extensions thereof) and for a period of two (2) years following the termination of the Executive’s employment under this Agreement for any reason, the Executive shall not, except with the Company’s express prior written consent, for the benefit of any entity or Person (including the Executive) (a) solicit, induce, or encourage any employee of the Company, or any of its affiliates, to leave the employment of the Company, or solicit, induce, or encourage any customer, client, or independent contractor of the Company, or any of its affiliates, to cease or reduce its business with or services rendered to the Company or its affiliates or (b) hire (on behalf of the Executive or any other person or entity) any employee or independent contractor who has left the employment or other service of the Company (or any predecessor thereof) within one year of the termination of such employee’s or independent contractor’s employment or other service with the Company.

 

  

9

  

 

8.4 Cooperation With Regard to Litigation.  The Executive agrees to cooperate with the Company, during the term and thereafter (including following the Executive’s termination of employment for any reason), by making himself available to testify on behalf of the Company or any affiliate of the Company, in any action, suit, or proceeding, whether civil, criminal, administrative, or investigative, and to assist the Company, or any affiliate of the Company, in any such action, suit, or proceeding, by providing information and meeting and consulting with the Board or its representatives or counsel, or representatives or counsel to the Company or any affiliate of the Company, as may be reasonably requested and after taking into account the Executive’s post-termination responsibilities and obligations.  The Company agrees to reimburse the Executive, on an after-tax basis, for all reasonable expenses actually incurred in connection with his provision of testimony or assistance.

 

8.5 Non-Disparagement.  The Executive shall not, at any time during the term of his employment and thereafter disparage the Company, its affiliates or their respective officers, directors or trustees, nor shall the Company, its affiliates or their respective officers, directors or trustees disparage Executive.  Notwithstanding the foregoing, nothing in this Agreement shall preclude the Executive or his successor or members of the Board from making truthful statements that are required by applicable law, regulation or legal process.

 

8.6 Survival.  The provisions of this Section 8 shall survive any termination or expiration of this Agreement.

 

8.7 Remedies.  The Executive agrees that any breach of the terms of this Section 8 would result in irreparable injury and damage to the Company for which the Company would have no adequate remedy at law; the Executive therefore also agrees that, in the event of said breach or any threat of breach and notwithstanding Section 9, the Company shall be entitled to an immediate injunction and restraining order from a court of competent jurisdiction to prevent such breach and/or threatened breach and/or continued breach by the Executive and/or any and all persons and/or entities acting for and/or with the Executive, without having to prove damages.  The availability of injunctive relief shall be in addition to any other remedies to which the Company may be entitled at law or in equity, but remedies other than injunctive relief may only be pursued in an arbitration brought in accordance with Section 9.  The terms of this paragraph shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach of this Section 8, including but not limited to the recovery of damages from the Executive.

 

  

10

  

 

9. Governing Law; Disputes; Arbitration.

 

9.1 Governing Law.  This Agreement is governed by and is to be construed, administered, and enforced in accordance with the laws of the State of Indiana, without regard to conflicts of law principles.  If under the governing law, any portion of this Agreement is at any time deemed to be in conflict with any applicable statute, rule, regulation, ordinance, or other principle of law, such portion shall be deemed to be modified or altered to the extent necessary to conform thereto or, if that is not possible, to be omitted from this Agreement.  The invalidity of any such portion shall not affect the force, effect, and validity of the remaining portion hereof.  If any court determines that any provision of Section 8 is unenforceable because of the duration or geographic scope of such provision, it is the parties’ intent that such court shall have the power to modify the duration or geographic scope of such provision, as the case may be, to the extent necessary to render the provision enforceable, and in its modified form, such provision shall be enforced.  If the courts of any one or more of jurisdictions hold Section 8 to be wholly unenforceable by reason of breadth of scope or otherwise, it is the intention of the Company and the Executive that such determination not bar or in any way affect the Company’s right, or the right of any of its affiliates, to the relief provided above in the courts of any other jurisdiction within the geographical scope of the provisions of Section 8, as to breaches of such provisions in such other respective jurisdictions, such provisions as they relate to each jurisdiction’s being, for this purpose, severable, diverse, and independent covenants, subject, where appropriate, to the doctrine of res judicata.

 

9.2 Arbitration.  Any dispute or controversy arising under or in connection with this Agreement shall be settled exclusively by arbitration in Indianapolis, Indiana by three (3) arbitrators.  The Executive and the Company shall each select one arbitrator and those two designated arbitrators shall select a third arbitrator.  The arbitration shall not be administered by the American Arbitration Association; however, the arbitration shall be conducted by the three selected arbitrators using the procedural rules of the Employment Arbitration Rules and Mediation Procedures of the American Arbitration Association in effect at the time of submission to arbitration.  Judgment may be entered on the arbitrators’ award in any court having jurisdiction.  For purposes of entering any judgment upon an award rendered by the arbitrators, the Company and the Executive hereby consent to the jurisdiction of any or all of the following courts:  (i) the United States District Court for the Southern District of Indiana, (ii) any of the courts of the State of Indiana, or (iii) any other court having jurisdiction.  The Company and the Executive further agree that any service of process or notice requirements in any such proceeding shall be satisfied if the rules of such court relating thereto have been substantially satisfied.  The Company and the Executive hereby waive, to the fullest extent permitted by applicable law, any objection which it may now or hereafter have to such jurisdiction and any defense of inconvenient forum.  The Company and the Executive hereby agree that a judgment upon an award rendered by the arbitrators may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.  Each party shall bear its or his costs and expenses arising in connection with any arbitration proceeding pursuant to this Section 9.  Notwithstanding any provision in this Section 9, the Executive shall be paid compensation due and owing under this Agreement during the pendency of any dispute or controversy arising under or in connection with this Agreement.

 

  

11

  

 

9.3 WAIVER OF JURY TRIAL.  TO THE EXTENT APPLICABLE, EACH OF THE PARTIES TO THIS AGREEMENT HEREBY AGREES TO WAIVE ITS RESPECTIVE RIGHTS TO A JURY TRIAL FOR ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY DEALINGS BETWEEN THEM RELATING TO THE SUBJECT MATTER OF THIS AGREEMENT.

 

10. Miscellaneous.

 

10.1 Integration.  This Agreement cancels and supersedes any and all prior agreements and understandings between the parties hereto with respect to the employment of the Executive by the Company, any parent or predecessor company, and the Company’s affiliates during the term, but excluding existing contracts relating to compensation under executive compensation and employment benefit plans of the Company and its affiliates.  This Agreement constitutes the entire agreement among the parties with respect to the matters herein provided, and no modification or waiver of any provision hereof shall be effective unless in writing and signed by the parties hereto.  The Executive shall not be entitled to any payment or benefit under this Agreement which duplicates a payment or benefit received or receivable by the Executive under such prior agreements and understandings or under any benefit or compensation plan of the Company.

 

10.2 Successors; Transferability.  The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation, or otherwise, and whether or not the corporate existence of the Company continues) to all or substantially all of the business and/or assets of the Company to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.  As used in this Agreement, “Company” shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law, or otherwise, and in the case of an acquisition of the Company in which the corporate existence of the Company continues, the ultimate parent company following such acquisition.  Subject to the foregoing, the Company may transfer and assign this Agreement and the Company’s rights and obligations hereunder to another entity that is substantially comparable to the Company in its financial strength and ability to perform the Company’s obligations under this Agreement.  Neither this Agreement nor the rights or obligations hereunder of the parties hereto shall be transferable or assignable by the Executive, except in accordance with the laws of the descent and distribution or as specified in Section 10.3.

 

10.3 Beneficiaries.  The Executive shall be entitled to designate (and change, to the extent permitted under applicable law) a beneficiary or beneficiaries to receive any compensation or benefits provided hereunder following the Executive’s death.

 

  

12

  

 

10.4 No Duty to Mitigate.  The Executive shall not be required to mitigate damages or the amount of any payment provided for under this Agreement by seeking other employment or otherwise, nor will any payments or benefits hereunder be subject to offset in the event the Executive does mitigate, except as provided in Section 5.2.

 

10.5 Notices.  Whenever under this Agreement it becomes necessary to give notice, such notice shall be in writing, signed by the party or parties giving or making the same, and shall be served on the person or persons for whom it is intended or who should be advised or notified, by Federal Express or other similar overnight service or by certified or registered mail, return receipt requested, postage prepaid and addressed to such party at the address set forth below or at such address as may be designated by such party by like notice:

 

If to the Company or the Board:

 

Kite Realty Group Trust

30 S. Meridian Street

Suite 1100

Indianapolis, IN 46204

Attn: Compensation Committee of the Board of Trustees, Chairperson

 

With a copy to:

 

Hogan Lovells US LLP

Columbia Square

555 Thirteenth Street, NW

Washington, DC 20004

Attn: David Bonser, Esq.

 

If to Executive, to the address set forth in the records of the Company.

 

If the parties by mutual agreement supply each other with fax numbers for the purpose of providing notice by facsimile, such notice shall also be proper notice under this Agreement.  Any notice, request, demand, claim, or other communication hereunder shall be deemed duly delivered (i) two (2) business days after it is sent by registered or certified mail, return receipt requested, postage prepaid, (ii) when received if it is sent by fax communication during normal business hours on a business day or one business day after it is sent by fax and received if sent other than during business hours on a business day, (iii) one business day after it is sent via a reputable overnight courier service, charges prepaid, or (iv) when received if it is delivered by hand.

 

10.6 Headings.  The headings of this Agreement are for convenience of reference only and do not constitute a part hereof.

 

  

13

  

 

10.7 Attorneys’ Fees.  In the event of any legal proceeding relating to this Agreement or any term or provision thereof, the losing party shall be responsible to pay or reimburse the prevailing party for all reasonable attorneys’ fees incurred by the prevailing party in connection with such proceeding; provided, however, the Executive shall not be required to pay or reimburse the Company unless the claim or defense asserted by the Executive was unreasonable.

 

10.8 No General Waivers.  The failure of any party at any time to require performance by any other party of any provision hereof or to resort to any remedy provided herein or at law or in equity shall in no way affect the right of such party to require such performance or to resort to such remedy at any time thereafter, nor shall the waiver by any party of a breach of any of the provisions hereof be deemed to be a waiver of any subsequent breach of such provisions.  No such waiver shall be effective unless in writing and signed by the party against whom such waiver is sought to be enforced.

 

10.9 Offsets; Withholding.  The amounts required to be paid by the Company to the Executive pursuant to this Agreement shall not be subject to offset.  The foregoing and other provisions of this Agreement notwithstanding, all payments to be made to Executive under this Agreement, including under Section 3, Section 4, and Section 5, or otherwise by the Company, will be subject to withholding to satisfy required withholding taxes and other required deductions.

 

10.10 Counterparts.  This Agreement may be executed in counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.

 

10.11 Representations of the Executive.  The Executive represents and warrants to the Company that (a) the information that he provided to the Company in connection with his application for employment with the Company is true and correct in all material respects, (b) he has the legal right to enter into this Agreement and to perform all of the obligations on his part to be performed hereunder in accordance with its terms and that (c) he is not a party to any agreement or understanding, written or oral, which prevents him from entering into this Agreement or performing all of his obligations hereunder.

 

10.12 Conflicting Terms.  Except as provided in Section 4 and Section 5.3, in the event of any conflict between the terms of this Agreement and the terms of any other compensation plan, agreement or award (including, without limitation, any annual or long term bonus and any equity based award), the terms and conditions of this Agreement shall govern and control.

 

11. Section 409A Savings Provisions.  It is intended that the payments and benefits provided under this Agreement shall be exempt from the application of the requirements of Section 409A of the Code and the regulations and other guidance issued thereunder (collectively, “Section 409A”). Specifically, any taxable benefits or payments provided under this Agreement are intended to be separate payments that qualify for the “short term deferral” exception to Section 409A to the maximum extent possible, and to the extent they do not so qualify, are intended to qualify for the separation pay exceptions to Section 409A, to the maximum extent possible.

 

  

14

  

 

11.1 Separation from Service.  The Executive will be deemed to have a termination of employment for purposes of determining the timing of any payments or benefits hereunder that are classified as deferred compensation only upon a “separation from service” within the meaning of Section 409A.

 

11.2 Specified Employee Provisions.  Notwithstanding any other provision of this Agreement to the contrary, if at the time of the Executive’s separation from service, (i) the Executive is a specified employee (within the meaning of Section 409A and using the identification methodology selected by the Company from time to time), and (ii) the Company makes a good faith determination that an amount payable on account of such separation from service to the Executive constitutes deferred compensation (within the meaning of Section 409A) the payment of which is required to be delayed pursuant to the six (6)-month delay rule set forth in Section 409A in order to avoid taxes or penalties under Section 409A (the “Delay Period”), then the Company will not pay such amount on the otherwise scheduled payment date but will instead pay it in a lump sum on the first business day after such Delay Period (or upon the Executive’s death, if earlier), together with interest for the period of delay, compounded annually, equal to the prime rate (as published in the Wall Street Journal) in effect as of the dates the payments should otherwise have been provided.  To the extent that any benefits to be provided during the Delay Period are considered deferred compensation under Section 409A provided on account of a “separation from service,” and such benefits are not otherwise exempt from Section 409A, the Executive shall pay the cost of such benefit during the Delay Period, and the Company shall reimburse the Executive, to the extent that such costs would otherwise have been paid by the Company or to the extent that such benefits would otherwise have been provided by the Company at no cost to the Executive, the Company’s share of the cost of such benefits upon expiration of the Delay Period, and any remaining benefits shall be reimbursed or provided by the Company in accordance with the procedures specified herein.

 

11.3 Expense Reimbursements.  (a) Any amount that the Executive is entitled to be reimbursed under this Agreement will be reimbursed to the Executive as promptly as practical and in any event not later than the last day of the calendar year after the calendar year in which the expenses are incurred; (b) any right to reimbursement or in kind benefits will not be subject to liquidation or exchange for another benefit; and (c) the amount of the expenses eligible for reimbursement during any taxable year will not affect the amount of expenses eligible for reimbursement in any other taxable year.

 

12. Definitions Relating to Termination Events.

 

12.1 Affiliate.  For purposes of this Agreement, an “affiliate” of any person means another person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first person, and includes subsidiaries.  Notwithstanding the foregoing, the persons listed on Exhibit B, as such Exhibit B is updated from time to time by the mutual agreement of the parties, shall not be affiliates of the Company.

 

12.2 Cause.  For purposes of this Agreement, “Cause” shall mean Executive’s:

 

(a) Conviction for (or pleading nolo contendere to) any felony;

 

  

15

  

 

(b) Commission of any act of fraud, theft, or dishonesty related to the business of the Company or its affiliates or the performance of the Executive’s duties hereunder;

 

(c) Willful and continuing failure or habitual neglect by the Executive to perform the Executive’s duties hereunder;

 

(d) Material violation of the covenants contained in Section 8; or

 

(e) Willful and continuing material breach of this Agreement.

 

For purposes of this Section 12.2, no act, or failure to act, by the Executive shall be considered “willful” unless committed in bad faith and without a reasonable belief that the act or omission was in the best interests of the Company or its affiliates.

 

12.3 Change in Control.  For purposes of this Agreement, “Change in Control” shall mean:

 

(a) The dissolution or liquidation of the Company;

 

(b) The merger, consolidation, or reorganization of the Company with one or more other entities in which the Company is not the surviving entity or immediately following which the persons or entities who were beneficial owners (as determined pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of voting securities of the Company immediately prior thereto cease to beneficially own more than fifty percent (50%) of the voting securities of the surviving entity immediately thereafter;

 

(c) A sale of all or substantially all of the assets of the Company to another person or entity;

 

(d) Any transaction (including without limitation a merger or reorganization in which the Company is the surviving entity) that results in any person or entity or “group” (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (other than persons who are shareholders or affiliates immediately prior to the transaction) owning thirty percent (30%) or more of the combined voting power of all classes of shares of the Company; or

 

(e) Individuals who, as of the date hereof, constitute the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a trustee subsequent to the date hereof whose election, or nomination for election by the Company’s shareholders, was approved by a vote of at least a majority of the trustees then comprising the Incumbent Board (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for trustee, without written objection to such nomination) shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of trustees or other actual or threatened solicitation of proxies or contests by or on behalf of a person other than the Board.

 

  

16

  

 

12.4 Compensation Accrued at Termination.  For purposes of this Agreement, “Compensation Accrued at Termination” means the following:

 

(a) The unpaid portion of annual Base Salary at the rate payable, in accordance with Section 2.1 hereof, at the Executive’s Termination Date, pro-rated through such Termination Date, payable in accordance with the Company’s regular pay schedule;

 

(b) Payment for vacation accrued under this Agreement but unused as of the Executive’s Termination Date;

 

(c) Except in the event the Executive’s employment is terminated for Cause (except to the extent otherwise required by law), all earned and unpaid and/or vested, nonforfeitable amounts owing or accrued at the Executive’s Termination Date under any compensation and benefit plans, programs, and arrangements set forth or referred to in Sections 2.2 and 2.3 hereof (including any earned and vested Annual Cash Incentive which the Company agrees is earned for purposes of this definition as of the close of business on the last day of the fiscal year) in which the Executive theretofore participated, payable (except as otherwise provided in Section 3, Section 4 and Section 5 of this Agreement) in accordance with the terms and conditions of the plans, programs, and arrangements (and agreements and documents thereunder) pursuant to which such compensation and benefits were granted or accrued; and

 

(d) Reasonable business expenses and disbursements incurred by the Executive prior to the Executive’s termination of employment, to be reimbursed to the Executive, as authorized under Section 2.6, in accordance with the Company’s reimbursement policies as in effect at the Executive’s Termination Date.

 

12.5 Disability.  For purposes of this Agreement, “Disability” means the Executive becomes eligible for disability benefits under the Company’s long-term disability plans and arrangements (or, if none apply, would have been so eligible under the most recent plan or arrangement).  This definition shall be interpreted and applied consistent with the Americans with Disabilities Act, the Family and Medical Leave Act, Section 409A of the Code, and other applicable law.

 

12.6 Good Reason.  For purposes of this Agreement, “Good Reason” shall mean, without the Executive’s express written consent, the occurrence of any of the following circumstances:

 

(a) The material reduction of the Executive’s authority, duties, and responsibilities, or the assignment to the Executive of duties materially and adversely inconsistent with the Executive’s position or positions with the Company and its affiliates;

 

(b) A material reduction in Base Salary of the Executive except in connection with a reduction in compensation generally applicable to senior management employees of the Company;

 

  

17

  

 

(c) The Company requiring the Executive to relocate his principal place of business for the Company to a location more than fifty (50) miles from the Company’s principal place of business in Indianapolis, Indiana;

 

(d) The failure by the Company to obtain an agreement in form and substance reasonably satisfactory to the Executive from any successor to the business of the Company to assume and agree to perform this Agreement; or

 

(e) The Company’s material breach of this Agreement.

 

12.7 Partial Year Bonus.  For purposes of this Agreement, “Partial Year Bonus” shall mean an amount equal to the product of (a) the Executive’s Full-Year Target Annual Cash Incentive for the fiscal year in which the Executive’s employment terminates and (b) a fraction, the numerator of which is the number of days in the current fiscal year through the Executive’s Termination Date, and the denominator of which is 365.

 

12.8 Pro-Rata Basis.  For purposes of this Agreement, vesting on a “Pro-Rata Basis” shall mean vesting in an amount equal to a fraction not to exceed one (1), the numerator of which is the number of days the Executive was employed by the Company from the grant date for such award to the Termination Date, and the denominator of which is the number of total days from the grant date to the date that otherwise would have resulted in full vesting of the award.

 

12.9 Termination Date.  For purposes of this Agreement, “Termination Date” shall mean: 

 

(a) The date that the Board delivers written notice to the Executive of his termination of employment for Cause or on account of Disability;

 

(b) The date set forth in a written notice delivered to the Executive of his termination of employment without Cause, which shall not be less than thirty (30) days after the date of such notice or more than sixty (60) days after the date of such notice;

 

(c) The date set forth in a written notice delivered to the Board of the Executive’s resignation, with or without Good Reason, which shall not be less than thirty (30) days after the date of such notice, except as otherwise mutually agreed to by the Company and the Executive;

 

(d) The June 30th following the date that the Executive or the Board provides the other party with notice of an election to terminate the automatic extension provision of Section 1.1(a), except as otherwise mutually agreed to by the Company and the Executive; or

 

(e) The date of the Executive’s death.

 

 

  

18

  

 

IN WITNESS WHEREOF, the parties hereto have signed their names as of the day and year first written above.

 

 

KITE REALTY GROUP TRUST

 

 

By:  _/s/ John A. Kite____________________________

 

Name:    John A. Kite

 

Title:      Chairman and Chief Executive Officer

 

 

 

EXECUTIVE

 

 

 

_/s/ Scott Murray_______________________________

    SCOTT MURRAY

 

 

  

19

  

 

SCHEDULE 1

 

 

REPORTING OFFICER

 

  

A-1

  

 

EXHIBIT A

 

EXCLUDED ACTIVITIES, PROPERTIES, AND INTERESTS

 

  

A-2

  

EXHIBIT B

 

 

EXCLUSION FROM AFFILIATES

 

  

B-1

  

EXHIBIT C

 

WAIVER AND RELEASE AGREEMENT

 

THIS WAIVER AND RELEASE AGREEMENT is entered into as of [TO BE DETERMINATED AT TERMINATION OF EMPLOYMENT], by Scott Murray (the “Executive”) in consideration of the severance pay and severance benefits to be provided to the Executive by Kite Realty Group Trust (the “Company”) pursuant to Section 5 of the Executive Employment Agreement (the “Employment Agreement”) by and between the Company and the Executive (the “Severance Payment”).

 

1. Waiver and Release.

 

(a) Subject to Section 1(b) of this Waiver and Release Agreement, the Executive, on his or her own behalf and on behalf of his or her heirs, executors, administrators, attorneys, and assigns, hereby unconditionally and irrevocably releases, waives, and forever discharges the Company and each of its affiliates, parents, successors, predecessors, and the subsidiaries, directors, owners, members, shareholders, officers, agents, and employees of the Company and its affiliates, parents, successors, predecessors, and subsidiaries (collectively, all of the foregoing are referred to as the “Employer”), from any and all causes of action, claims, and damages, including attorneys’ fees, whether known or unknown, foreseen or unforeseen, presently asserted or otherwise arising through the date of his or her signing of the Waiver and Release Agreement, concerning his or her employment or separation from employment.  Subject to Section 1(b) of this Waiver and Release Agreement, this release includes, but is not limited to, any payments, benefits, or damages arising under any federal law (including, but not limited to, Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act, the Employee Retirement Income Security Act of 1974, the Americans with Disabilities Act, Executive Order 11246, the Family and Medical Leave Act, and the Worker Adjustment and Retraining Notification Act, each as amended); any claim arising under any state or local laws, ordinances, or regulations (including, but not limited to, any state or local laws, ordinances, or regulations requiring that advance notice be given of certain workforce reductions); and any claim arising under any common law principle or public policy, including, but not limited to, all suits in tort or contract, such as wrongful termination, defamation, emotional distress, invasion of privacy, or loss of consortium.

 

(b) Notwithstanding any other provision of this Waiver and Release Agreement to the contrary, this Waiver and Release Agreement does not encompass, and Executive does not release, waive or discharge, the obligations of the Company (i) to make the payments and provide the other benefits contemplated by the Employment Agreement or any other agreement with Executive, (ii) under any award agreement entered into with the Executive pursuant to the Kite Realty Group Trust 2013 Equity Incentive Plan, as amended from time to time, and any successor plan thereto, (iii) under any indemnification or similar agreement with Executive, or (iv) under this Waiver and Release Agreement.

 

  

C-1

  

 

(c) The Executive understands that by signing this Waiver and Release Agreement that he or she is not waiving any claims or administrative charges which cannot be waived by law.  He or she is waiving, however, any right to monetary recovery or individual relief should any federal, state, or local agency (including the Equal Employment Opportunity Commission) pursue any claim on his or her behalf arising out of or related to his or her employment with and/or separation from employment with the Company (other than with respect to those matters described in Section 1(b) of this Waiver and Release Agreement ).

 

(d) The Executive further agrees without any reservation whatsoever, never to sue the Employer or become a party to a lawsuit on the basis of any and all claims of any type lawfully and validly released in this Waiver and Release Agreement.

 

2. Acknowledgments.

 

  The Executive is signing this Waiver and Release Agreement knowingly and voluntarily.  He or she acknowledges that:

 

(a) He or she is hereby advised in writing to consult an attorney before signing this Waiver and Release Agreement;

 

(b) He or she has relied solely on his or her own judgment and/or that of his or her attorney regarding the consideration for and the terms of the Waiver and Release Agreement and is signing this Waiver and Release Agreement knowingly and voluntarily of his or her own free will;

 

(c) He or she is not entitled to the Severance Payment unless he or she agrees to and honors the terms of this Waiver and Release Agreement and continues to honor the surviving terms of the Employment Agreement, including, but not limited to, Section 8 (Confidentiality; Non-Competition and Non-Disclosure; Executive Cooperation; Non-Disparagement) of the Employment Agreement ;

 

(d) He or she has been given at least forty-five (45) calendar days to consider this Waiver and Release Agreement, or he or she expressly waives his or her right to have at least forty-five (45) days to consider this Waiver and Release Agreement;

 

(e) He or she may revoke this Waiver and Release Agreement within seven (7) calendar days after signing it by submitting a written notice of revocation to the Company.  He or she further understands that this Waiver and Release Agreement is not effective or enforceable until after the seven (7) day period of revocation has expired without revocation, and that if he or she revokes this Waiver and Release Agreement within the seven (7) day revocation period, he or she will not receive the Severance Payment;

 

(f) He or she has read and understands the Waiver and Release Agreement and further understands that, subject to the limitations contained herein, it includes a general release of any and all known and unknown, foreseen and unforeseen claims presently asserted or otherwise arising through the date of his or her signing of this Waiver and Release Agreement that he or she may have against the Employer; and

 

  

C-2

  

 

(g) No statements made or conduct by the Employer has in any way coerced or unduly influenced him or her to execute this Waiver and Release Agreement.

 

3. No Admission of Liability.

 

  This Waiver and Release Agreement does not constitute an admission of liability or wrongdoing on the part of the Employer; the Employer does not admit there has been any wrongdoing whatsoever against the Executive; and the Employer expressly denies that any wrongdoing has occurred.

 

4. Entire Agreement.

 

  There are no other agreements of any nature between the Employer and the Executive with respect to the matters discussed in this Waiver and Release Agreement, except as expressly stated herein, and in signing this Waiver and Release Agreement, the Executive is not relying on any agreements or representations, except those expressly contained in this Waiver and Release Agreement.

 

5. Execution.

 

  It is not necessary that the Employer sign this Waiver and Release Agreement following the Executive’s full and complete execution of it for it to become fully effective and enforceable.

 

6. Severability.

 

  If any provision of this Waiver and Release Agreement is found, held, or deemed by a court of competent jurisdiction to be void, unlawful, or unenforceable under any applicable statute or controlling law, the remainder of this Waiver and Release Agreement shall continue in full force and effect.

 

7. Governing Law.

 

  This Waiver and Release Agreement shall be governed by the laws of the State of Indiana, excluding the choice of law rules thereof.

 

8. Headings.

 

  Section and subsection headings contained in this Waiver and Release Agreement are inserted for the convenience of reference only.  Section and subsection headings shall not be deemed to be a part of this Waiver and Release Agreement for any purpose, and they shall not in any way define or affect the meaning, construction, or scope of any of the provisions hereof.

 

IN WITNESS WHEREOF, the undersigned has duly executed this Waiver and Release Agreement as of the day and year first herein above written.

 

EXECUTIVE

 

 

________________________________________

 

  

C-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]